L3Harris Technologies Capitalized research and experimental expenditures decreased by 26.5% to $1.25B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 26.5%, from $1.69B to $1.25B. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates higher R&D investment that will provide tax shields in future periods as the costs are amortized.
This reflects the deferred tax asset created when research and experimental expenditures are capitalized for tax purpose...
Highly comparable among R&D-intensive firms, especially following recent changes to tax laws regarding R&D expense treatment.
other_deferred_tax_assets_deferred_expense_capitalized_r_65c82b| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $0.00 | $646.00M | $1.13B | $1.69B | $1.25B |
| QoQ Change | — | — | +74.1% | +50.6% | -26.5% |
| YoY Change | — | — | +74.1% | +50.6% | -26.5% |